{"organizations": [], "uuid": "d6def4bdb85d3604efebb2784cbcd8529223451e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-concert-pharma-says-intends-to-com/brief-concert-pharma-says-intends-to-complete-evaluation-and-advance-ctp-692-into-clinical-development-by-2018-end-idUSFWN1QI1JG", "country": "US", "domain_rank": 408, "title": "BRIEF-Concert Pharma Says Intends To Complete Evaluation And Advance CTP-692 Into Clinical Development By 2018 End", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.152, "site_type": "news", "published": "2018-03-01T05:26:00.000+02:00", "replies_count": 0, "uuid": "d6def4bdb85d3604efebb2784cbcd8529223451e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-concert-pharma-says-intends-to-com/brief-concert-pharma-says-intends-to-complete-evaluation-and-advance-ctp-692-into-clinical-development-by-2018-end-idUSFWN1QI1JG", "ord_in_thread": 0, "title": "BRIEF-Concert Pharma Says Intends To Complete Evaluation And Advance CTP-692 Into Clinical Development By 2018 End", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "concert pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 28 (Reuters) - Concert Pharmaceuticals Inc:\n* CONCERT PHARMACEUTICALS INC SAYS INTENDS TO COMPLETE PRECLINICAL EVALUATION AND ADVANCE CTP-692 INTO CLINICAL DEVELOPMENT BY YEAR-END 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-01T05:26:00.000+02:00", "crawled": "2018-03-01T21:11:11.021+02:00", "highlightTitle": ""}